Adalimumab
BiologicalAdalimumab 40 mg by subcutaneous injection every other week or every week
Other names: ABT-D2E7, Humira
NCT Number: NCT00195715
To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 3
Site Ref # / Investigator 1938, Camperdown, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Adalimumab 40 mg by subcutaneous injection every other week or every week
Other names: ABT-D2E7, Humira
Time frame: Week 156
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 48
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 108
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 204
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
A CR-100 is a decrease from baseline in CDAI score of 100 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
A CR-70 is a decrease from baseline in CDAI score of 70 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Steroid-free remission was achieved if the subject stopped taking steroids before the visit and had a Crohn's Disease Activity Index (CDAI) score of <150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Steroid-free CR-100 was achieved if the subject stopped taking steroids before the visit and had a decrease from baseline in CDAI score of 100 or more points at that visit. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.
Time frame: Week 156
Fistula remission was defined as the absence of draining fistulas in subjects with fistula present at the preceding study's baseline visit.
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Serious infections are infectious adverse events that meet at least one criterion for a serious adverse event (e.g., death, life threatening event, hospitalization) including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and infections due to other opportunistic pathogens.
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
An injection site reaction is any adverse event corresponding to a preferred term beginning with "injection site" excluding injection site arthritis, injection site movement impairment, injection site photosensitivity, injection site joint effusion, injection site joint inflammation, injection site scab, injection site joint pain, or injection site laceration.
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Time frame: Up to 262 weeks of adalimumab treatment
Abbott
Industry
A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03000101
Colitis, Colitis, Ulcerative
Bologna, Italy
View Trial DetailsNCT07697547
Crohn Disease, Crohn's Disease
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT01155362
Crohn Disease, Crohn's Disease
Los Angeles, California, United States
View Trial DetailsNCT04002180
Crohn Disease, Crohn's Disease
Tokyo, Japan
View Trial Details